Gulati, R; Fleifil, Y; Jennings, K; Bondoc, A; Tiao, G; Geller, J; Timchenko, L; Timchenko, N. Inhibition of Histone Deacetylase Activity Increases Cisplatin Efficacy to Eliminate Metastatic Cells in Pediatric Liver Cancers. Cancers. 2024; 16.

Gulati, R; Timchenko, N. C/EBPα-mediated epigenetic control of liver disorders in young children. 2024; 5:23-27.

Glaser, K; Schepers, EJ; Zwolshen, HM; Lake, CM; Timchenko, NA; Karns, RA; Cairo, S; Geller, JI; Tiao, GM; Bondoc, AJ. EZH2 is a key component of hepatoblastoma tumor cell growth. Pediatric Blood and Cancer. 2024; 71:e30774.

Gulati, R; Lutz, M; Hanlon, M; Cast, A; Karns, R; Geller, J; Bondoc, A; Tiao, G; Timchenko, L; Timchenko, NA. Cellular origin and molecular mechanisms of lung metastases in patients with aggressive hepatoblastoma. Hepatology Communications. 2024; 8.

Hanlon, MA; Gulati, R; Johnston, M; Fleifil, Y; Rivas, M; Timchenko, NA. Genetic Ablation of C/EBPα-p300 Pathway Blocks Development of Obese Pregnancy Associated Liver Disorders in Offspring. CMGH Cellular and Molecular Gastroenterology and Hepatology. 2024; 17:347-360.

Brown, A; Pan, Q; Fan, L; Indersie, E; Tian, C; Timchenko, N; Li, L; Hansen, BS; Tan, H; Lu, M; Peng, J; Pruett-Miller, SM; Yu, J; Cairo, S; Zhu, L. Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse. Communications Biology. 2023; 6:249.

Lutz, M; Levanti, M; Karns, R; Gourdon, G; Lindquist, D; Timchenko, NA; Timchenko, L. Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy. International Journal of Molecular Sciences. 2023; 24.

Gulati, R; Hanlon, MA; Lutz, M; Quitmeyer, T; Geller, J; Tiao, G; Timchenko, L; Timchenko, N. Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma. Cancers. 2022; 14.

Gulati, R; Johnston, M; Rivas, M; Cast, A; Kumbaji, M; Hanlon, MA; Lee, S; Zhou, P; Lake, C; Schepers, E; Geller, J; Tiao, G; Shin, S; Timchenko, N. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma. Hepatology Communications. 2022; 6:2950-2963.

D’souza, AM; Gnanamony, M; Thomas, M; Hanley, P; Kanabar, D; de Alarcon, P; Muth, A; Timchenko, N. Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer. Cancers. 2022; 14.

Johnston, ME; Timchenko, N. Molecular signatures of aggressive pediatric liver cancer. 2021; 2:1-4.

Johnston, ME; Rivas, MP; Nicolle, D; Gorse, A; Gulati, R; Kumbaji, M; Weirauch, MT; Bondoc, A; Cairo, S; Geller, J; Tiao, G; Timchenko, N. Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. Hepatology. 2021; 74:2201-2215.

D’Souza, AM; Cast, A; Kumbaji, M; Rivas, M; Gulati, R; Johnston, M; Smithrud, D; Geller, J; Timchenko, N. Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin. Frontiers in Pharmacology. 2021; 12:580722.

Timchenko, NA. Help for Sick Kids: New Insights Into Hepatoblastoma. CMGH Cellular and Molecular Gastroenterology and Hepatology. 2021; 12:350-351.

Rivas, M; Johnston, ME; Gulati, R; Kumbaji, M; Margues Aguiar, TF; Timchenko, L; Krepischi, A; Shin, S; Bondoc, A; Tiao, G; Geller, J; Timchenko, N. HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer. CMGH Cellular and Molecular Gastroenterology and Hepatology. 2021; 12:1669-1682.

Rivas, MP; Aguiar, TF M; Maschietto, M; Lemes, RB; Caires-Júnior, LC; Goulart, E; Telles-Silva, KA; Novak, E; Cristofani, LM; Odone, V; Pearson, PL; Rosenberg, C; Timchenko, N; Krepischi, AC V. Hepatoblastomas exhibit marked NNMT downregulation driven by promoter DNA hypermethylation. Tumor Biology: from basic science to clinical application. 2020; 42:1010428320977124.